Pages that link to "Q28250267"
Jump to navigation
Jump to search
The following pages link to Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India (Q28250267):
Displaying 26 items.
- Health economic evaluations of visceral leishmaniasis treatments: a systematic review (Q28084540) (← links)
- Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis (Q28271849) (← links)
- Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent (Q28475431) (← links)
- Live vaccination tactics: possible approaches for controlling visceral leishmaniasis (Q28542081) (← links)
- Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia (Q28741732) (← links)
- Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs (Q33828879) (← links)
- Structures, Targets and Recent Approaches in Anti-Leishmanial Drug Discovery and Development (Q35012968) (← links)
- Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans (Q35168703) (← links)
- The economic value of a visceral leishmaniasis vaccine in Bihar state, India (Q35771782) (← links)
- Short-Course Treatment Regimen of Indian Visceral Leishmaniasis with an Indian Liposomal Amphotericin B Preparation (Fungisome™). (Q36455848) (← links)
- Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex. (Q37263800) (← links)
- Drug combinations for visceral leishmaniasis (Q37792751) (← links)
- Assessing the quality of pharmacoeconomic studies in India: a systematic review (Q38020528) (← links)
- A Systematic Review of the State of Economic Evaluation for Health Care in India (Q38602629) (← links)
- Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar). (Q39599468) (← links)
- Study of implementation and direct cost estimates for diagnostic tests for human visceral leishmaniasis in an urban area in Brazil (Q40342021) (← links)
- 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis (Q40810593) (← links)
- Biomimetically engineered Amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals (Q41703512) (← links)
- Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health (Q43167558) (← links)
- Leishmaniasis in humans: drug or vaccine therapy? (Q47556262) (← links)
- Reduced pathogenicity of fructose-1,6-bisphosphatase deficient Leishmania donovani and its use as an attenuated strain to induce protective immunogenicity (Q48514720) (← links)
- Cost-effectiveness analysis of diagnostic tests for human visceral leishmaniasis in Brazil (Q50150753) (← links)
- Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis. (Q50677795) (← links)
- Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial (Q56804080) (← links)
- Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases (Q57347954) (← links)
- Visceral Leishmaniasis - Current Treatments and Needs (Q59003562) (← links)